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ABSTRACT
Tuberculosis is a leading cause of morbidity and mortality worldwide. Susceptibility testing of the
causative agent, Mycobacterium tuberculosis, is critical for control of the disease. This study compared the
ﬂow cytometric susceptibility assay with the proportion method and the BACTEC TB-460 system. There
was agreement between the ﬂow cytometric and proportion methods for 73 (94%) of 78 isoniazid tests,
and complete agreement for 26 ethambutol and rifampicin tests. In contrast, the proportion and
BACTEC methods failed to agree for 22%, 15% and 8% of isoniazid, ethambutol and rifampicin tests,
respectively. These ﬁndings indicated that susceptibility testing by the ﬂow cytometric assay is accurate,
with results available within 24 h of initiation of the testing procedure.
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INTRODUCTION
The USA Centers for Disease Control and Preven-
tion consider that susceptibility testing of Myco-
bacterium tuberculosis is critical for treatment of
tuberculosis patients and control of the disease [1].
Unfortunately, susceptibility testing ofM. tubercu-
losis is limited by the time required to obtain
results, primarily because of the slow growth of
the organism. Conventional methods of anti-
mycobacterial susceptibility testing, such as the
proportion method, require incubation for
c. 3 weeks before results are available [2–4]. Even
the method used most frequently, BACTEC-460,
requires incubation for 4–12 days [4–8]. Therefore,
newer methods are being developed constantly to
facilitate more rapid availability of susceptibility
results [9–18].
Previous studies have reported that suscepti-
bility testing of M. tuberculosis could be accom-
plished rapidly by using a ﬂow cytometer [18–20].
The method is based on the ability of viable
M. tuberculosis cells to accumulate 5-chlorometh-
ylﬂuorescein diacetate (FDA) and hydrolyse the
compound rapidly to free ﬂuorescein by intrinsic
cellular esterases [21–23]. The ﬂuorescein accu-
mulates in viable cells, while dead cells, or
mycobacterial cells inhibited by anti-mycobacte-
rial agents, hydrolyse signiﬁcantly less FDA. The
differences in ﬂuorescein concentrations within
viable or killed and inhibited mycobacteria can be
distinguished easily by ﬂow cytometric analysis.
Multiplication of M. tuberculosis is not required,
and reproducible results are available within 24 h
[18,19].
In the present study, evidence is provided that
the ﬂow cytometric susceptibility assay is valu-
able for performing routine susceptibility testing
of M. tuberculosis. The results of anti-tuberculosis
susceptibility tests obtained by the proportion,
BACTEC-460 and ﬂow cytometric methods were
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compared using M. tuberculosis isolates with
varied susceptibility patterns to ethambutol,
isoniazid and rifampicin.
MATERIALS AND METHODS
Anti-mycobacterial agents
Ethambutol, isoniazid and rifampicin were obtained from
Sigma Chemical Co. (St Louis, MO, USA). Stock solutions
(10 mg ⁄mL) of ethambutol and isoniazid were prepared in
distilled water, sterilised by ﬁltration through a 0.2-lm ﬁlter
and stored at ) 70C in 1.0-mL aliquots until used. Rifampicin
(10 mg ⁄mL) was prepared similarly, except that it was
prepared in dimethylsulphoxide (Sigma).
Mycobacteria and preparation
Twenty-six clinical isolates of M. tuberculosis with varied
resistance to ethambutol, isoniazid and rifampicin were
obtained from the Centers for Disease Control and Prevention
and the Wisconsin State Laboratory of Hygiene. Reference
M. tuberculosis strains ATCC 27294, 35822, 35838 and 35837
were also included in the study. Each isolate was grown from
frozen stock in 10 mL of 7H9 broth (Wisconsin State Labor-
atory, WI, USA) in a sterile 10-mL glass screw-cap tube at 37C
in the presence of CO2 5% v ⁄v until the turbidity of
the suspension was equivalent to a McFarland 1.0 standard
(c. 5–14 days).
Agar proportion susceptibility testing
An agar proportion method, similar to that recommended by
the NCCLS [2,4], was used to determine the percentage of
M. tuberculosis cells resistant to each of the concentrations of
anti-mycobacterial agents tested. Brieﬂy, ethambutol, isoniazid
and rifampicin were added to 7H10 medium, and held at 50–
52C, to yield ﬁnal concentrations of ethambutol 5 mg ⁄L,
isoniazid 0.2, 1 and 5 mg ⁄L, and rifampicin 1 mg ⁄L. Subse-
quently, 5 mL of medium containing each anti-mycobacterial
agent was dispensed into labelled quadrants of sterile Petri
plates. One quadrant was reserved for 7H10 medium without
any anti-tuberculosis agent. After solidiﬁcation, the plates
were inoculated with 0.1 mL of 10)2 and 10)4 dilutions of a
McFarland 1.0 suspension of each isolate of M. tuberculosis,
and then incubated at 37C in CO2 5% v ⁄v for 3 weeks. An
isolate was considered susceptible to an anti-mycobacterial
agent if the number of colonies that grew on the drug-
containing plate was < 1% of the number of colonies that grew
on the drug-free control. An isolate was considered resistant if
‡ 1% grew on the drug-containing plate.
Radiometric broth method (BACTEC)
Initially, 7H9 broths were inoculated (1 mL) with an isolate of
M. tuberculosis and incubated (5–14 days) until turbidity
matched a McFarland 1.0 standard (3 · 108 CFU ⁄mL); this
was followed by inoculation (0.1 mL) of a BACTEC 12B vial
(Becton Dickinson Diagnostic Instrument Systems, Sparks,
MD, USA). After incubation for 2–7 days at 37C, aliquots
(0.1 mL) of each working suspension with a growth index (GI)
of 999 detected with the BACTEC 460 instrument (Becton
Dickinson) were diluted 1:10 and 1:100 with BACTEC diluent.
Subsequently, 0.1 mL of each of the diluted suspensions was
used to inoculate drug-containing BACTEC 12B vials (etham-
butol 2.5 mg ⁄L; isoniazid 0.1, 0.4 and 2.5 mg ⁄L; rifampicin
2 mg ⁄L), together with a drug-free control. The vials were
incubated at 37C and tested in the BACTEC 460 instrument at
approximately the same time each day. The MIC was inter-
pretable when the GI of the 1:100 control read 20 or more for
three consecutive days while the GI of the undiluted control
read 999. It was necessary for these requirements to be met
between days 4 and 8 of incubation for the test to be
considered valid. The MIC was the lowest concentration of
the anti-mycobacterial agent that inhibited 99% of the bacterial
population. The ﬁnal GI was <50.
Flow cytometric susceptibility test
An aliquot (0.9 mL) of each actively growing M. tuberculosis
isolate was transferred to a 2-mL screw-cap microtube (Sar-
stedt, Newton, NC, USA). Solutions of isoniazid 50, 10 or
2 mg ⁄L, ethambutol 50 mg ⁄L or rifampicin 10 mg ⁄L were
then added (0.1 mL) to each tube. In other experiments, tubes
containing 0.9 mL of mycobacterial suspension were supple-
mented (0.1 mL) with isoniazid 50, 25, 10, 5, 2, 1.2 and
0.6 mg ⁄L. Drug-free suspensions of M. tuberculosis were
included as controls. The suspensions were incubated for
24 h at 37C in the presence of CO2 5% v ⁄v. After incubation,
0.2 mL of each suspension was removed and placed in a sterile
2-mL screw-cap microtube containing 0.2 mL of FDA (Molecu-
lar Probes, Eugene, OR, USA), prepared fresh on a daily basis
at 500 ng ⁄mL in phosphate-buffered saline, pH 7.4. The
samples were then incubated at 37C for 30 min before being
analysed with a Bryte HS ﬂow cytometer with WinBryte
software (Bio-Rad Laboratories, Hercules, CA, USA).
Initially, unstained viableM. tuberculosis cells were detected
and differentiated from non-M. tuberculosis particles in 7H9
medium by forward and side angle light scatter. Background
events (particles) in the 7H9 medium and electronic noise were
eliminated by thresholding. Subsequently, viable M. tubercu-
losis cells, incubated in the presence or absence of anti-
mycobacterial agents for 24 h, were stained with FDA. For
each isolate, at each concentration of anti-mycobacterial agent,
the ﬂow cytometer provided a histogram relating the number
of M. tuberculosis cells in each of 2048 logarithmic channels of
increasing ﬂuorescence intensity, a mean channel ﬂuorescence
value, and a contour plot relating forward angle light scatter
and intensity of ﬂuorescence. In total, 2–10 000 events were
acquired for each sample. In addition, ﬂuorescent polystyrene
beads with a diameter of 1.5 lm (Bio-Rad) were used daily for
calibration of the instrument.
Flow cytometric susceptibility index
The susceptibility indexwasdetermined from themean channel
ﬂuorescence value obtained from histogram proﬁles (channels
0–2048) of the population of FDA-stainedM. tuberculosis cells in
the presence or absence of anti-mycobacterial agents [18].
Subsequently, these valueswere dividedby 512, i.e., the number
of channels per log decade. The antilogwas then determined for
these values to obtain the relative linear ﬂuorescence value for
each sample analysed. Finally, the relative ﬂuorescence value of
each drug-containing sample was divided by the relative
ﬂuorescence value of the drug-free control to obtain the
susceptibility index for each isolate. An isolate ofM. tuberculosis
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was considered susceptible to an anti-mycobacterial agent if the
susceptibility index was £ 0.75. This value was set before
experimentation. The calculation eliminated any variability
among the isolates ofM. tuberculosis in their ability to hydrolyse
FDA in the absence of anti-mycobacterial agents.
Data reporting
The isoniazid concentrations used in the BACTEC method (0.1,
0.4 and 2.5 mg ⁄L) were equivalent to concentrations of 0.2, 1
and 5 mg ⁄L used in the proportion [4] and ﬂow cytometric
methods. Likewise, ethambutol 2.5 mg ⁄L and rifampicin
2 mg ⁄L were used in the BACTEC method, while ethambutol
5 mg ⁄L and rifampicin 1 mg ⁄L were assayed in the proportion
[4] and ﬂow cytometric methods. To simplify reporting of data,
BACTEC concentrations are listed as isoniazid 0.2, 1 and
5 mg ⁄L, ethambutol 5 mg ⁄L, and rifampicin 1 mg ⁄L.
RESULTS
Susceptibility of clinical isolates of
M. tuberculosis to anti-mycobacterial agents
Table 1 lists the results obtained by the BACTEC,
ﬂow cytometric and proportion methods for 26
clinical isolates of M. tuberculosis with different
susceptibilities to isoniazid, rifampicin and
ethambutol. There was 94% agreement (73 ⁄ 78
tests) between the proportion and ﬂow cytometric
methods for isoniazid. Three of the ﬁve discrep-
ancies (isolates 15, 16 and 23) occurred with
isoniazid 0.2 mg ⁄L. The remaining discrepancies
occurred with isolates 19 and 20 at isoniazid 1 and
5 mg ⁄L, respectively. These ﬁve isolates were
classed as resistant to isoniazid by the proportion
method, but as susceptible to isoniazid by the ﬂow
cytometric method. No discrepancies between the
methods were detected when susceptibility to
ethambutol or rifampicin was tested for the 26
isolates.
In contrast, there was considerable disagree-
ment between the proportion and BACTEC meth-
ods regarding susceptibility to isoniazid, with 17
(22%) discrepancies among the 78 tests. Nine of
the discrepancies occurred with isoniazid
0.2 mg ⁄L. Isolates 1, 11, 14, 15, 16, 23 and 24
were resistant to isoniazid by the proportion
method, but susceptible by the BACTEC method.
The remaining isolates (5 and 12) were susceptible
by the proportion method, but resistant by the
Table 1. Results of susceptibility
tests for 26 isolates of Mycobacterium
tuberculosis exposed to isoniazid
(INH), rifampicin (RIF) and etham-
butol (EMB) by the proportion, ﬂow
cytometric and BACTEC methods
Isolate
Susceptibility to indicated concentrations of INH, RIF and EMB (mg/L)
Proportion method Flow cytometric method BACTEC methoda
INH RIF EMB INH RIF EMB INH RIF EMB
0.2 1 5 1 5 0.2 1 5 1 5 0.2 1 5 1 5
1 |R| S S S S R S S S S |S| S S S S
2 R R |S| S S R R S S S R R |R| S S
3 R |S| S S S R S S S S R |R| S S S
4 S S S |R| S S S S R S S S S |S| S
5 |S| S S |R| S S S S R S |R| S S |S| S
6 S S S R S S S S R S S S S R S
7 R R |S| S S R R S S S R R |R| S S
8 R R R S S R R R S S R R R S S
9 R R R S R R R R S R R R R S R
10 S S S R S S S S R S S S S R S
11 |R| S S S S R S S S S |S| S S S S
12 |S| |S| S R S S S S R S |R| |R| S R S
13 R R |S| S S R R S S S R R |R| S S
14 |R| S S |S| S R S S S S |S| S S |R| S
15 |R|B S S S S S S S S S |S| S S S S
16 |R| S S S S S S S S S |S| S S S S
17 R R S S S R R S S S R R S S S
18 R R |S| S S R R S S S R R |R| S S
19 R R |S| S R R S S S R R R |R| S R
20 R R R S S R R S S S R R R S S
21 R |S| S S |S| R S S S S R |R| S S |R|
22 R R R S R R R R S R R R R S R
23 |R| S S R S S S S R S |S| S S R S
24 |R| S S S |R| R S S S R |S| S S S |S|
25 S S S |R| S S S S R S S S S |S| S
26 S S S R S S S S R S S S S R S
Bold type indicates discrepancies between the ﬂow cytometric and BACTEC methods.
Underlining indicates discrepancies between the ﬂow cytometric and proportion methods.
Vertical lines indicate discrepancies between the proportion and BACTEC methods.
aThe INH concentrations used in the BACTEC method were 0.1, 0.4 and 2.5 mg ⁄L, equivalent to 0.2, 1 and 5 mg ⁄L
used in the proportion [4] and ﬂow cytometric methods. Likewise, EMB 2.5 mg ⁄L and RIF 2 mg ⁄L were used (see
text).
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BACTEC method. Furthermore, eight discrepan-
cies were detected with isoniazid 1 and 5 mg ⁄L,
with isolates 2, 3, 7, 12, 13, 18, 19 and 21
susceptible by the proportion method, but resist-
ant by the BACTEC method.
When susceptibility to ethambutol and rifampi-
cin was tested by the proportion and BACTEC
methods, an additional six discrepancies were
found. Three isolates (4, 5 and 25) were resistant
to rifampicin by the proportion method, but
susceptible by the BACTEC method. The remain-
ing isolate (14) was susceptible to rifampicin by
the proportion method, but resistant by the
BACTEC method. Furthermore, contrasting eth-
ambutol susceptibility results were obtained for
isolates 21 and 24 by these two methods.
The susceptibility results were also compared
between the ﬂow cytometric and BACTEC meth-
ods. Sixteen (20%) discrepancies were found
when testing isonaizid susceptibility, while four
(15%) and two (8%) discrepancies, respectively,
were detected when testing rifampicin and eth-
ambutol susceptibilities. These percentages were
similar to those obtained when the BACTEC
method was compared with the proportion
method. Table 2 summarises the above results.
No discrepancies were found among the test
methods when the reference strains ATCC 27294,
35822, 35838 and 35837 were tested.
Analysis of discordant results
Five isolates (15, 16, 19, 20 and 23) accounted for
all the isoniazid discrepancies between the pro-
portion and the ﬂow cytometric methods. Since
the proportion method is considered to be the
reference method [2,4], the ﬂow cytometric sus-
ceptibility tests were repeated with these isolates,
but identical results were obtained. When a
broader range of isoniazid concentrations (0.06–
5 mg ⁄L) was tested by the ﬂow cytometric assay
(Table 3), four of the ﬁve isolates (15, 16, 19 and
23) were susceptible to a lower concentration of
isoniazid than observed previously with the same
method (0.12, 0.12, 0.5 and 0.06 mg ⁄L, respect-
ively). However, isolate 20 remained susceptible
only to isoniazid 5 mg ⁄L. Most likely, the resist-
ant result obtained by the proportion method was
correct.
Effects of inoculum size on ﬂow cytometric
results
Three isolates (1, 11 and 14) were selected because
they were resistant to isoniazid £ 0.2 mg ⁄L.
Table 4 shows the susceptibility patterns of these
isolates over a range of isoniazid concentrations
from 0.06 to 5 mg ⁄L. These isolates were resistant
to isoniazid 0.2 mg ⁄L with an inoculum of
106 CFU ⁄mL, but were susceptible to 0.12 mg ⁄L
when the inoculum was reduced to 104 CFU ⁄mL.
Table 2. Summary of discrepancies observed between
susceptibility testing methods for isoniazid, rifampicin
and ethambutol with 26 isolates of Mycobacterium tubercu-
losis
Methods
Number of discrepancies observed with the indicated
concentrations (mg/L)
Isoniazid Rifampicin Ethambutol
0.2a 1 5 % 1 % 5 %
Proportion vs.
ﬂow cytometry
3 1 1 6 0 0
Proportion vs.
BACTEC
9 3 5 22 4 15 2 8
Flow cytometry vs.
BACTEC
6 4 6 20 4 15 2 8
There were 26 tests ⁄ concentration of anti-mycobacterial agent.
aThe isoniazid concentrations used in the BACTEC method were 0.1, 0.4 and
2.5 mg ⁄L, equivalent to 0.2, 1 and 5 mg ⁄L used in the proportion [4] and ﬂow
cytometric methods. Likewise, ethambutol 2.5 mg ⁄L and rifampicin 2 mg ⁄L were
used (see text).
Table 3. MICs of isoniazid obtained by ﬂow cytometry for
discordant isolates
Discordant isolates
Susceptibility to indicated concentrations of isoniazid
(mg/L)
0.06 0.12 0.2 0.5 1.0 2.5 5.0
15 R S S S S S S
16 R S S S S S S
19 R R R S S S S
20 R R R R R R S
23 S S S S S S S
R, resistant; S, susceptible.
Table 4. Effect of inoculum size on isoniazid susceptibility
results obtained by ﬂow cytometry
Isolate no. Inoculum size
Susceptibility to indicated concentration of
isoniazid (mg/L)
0.06 0.12 0.2 0.5 1.0 2.5 5.0
1 106 R R R S S S S
104 R S S S S S S
11 106 R R R S S S S
104 R S S S S S S
14 106 R R R S S S S
104 R S S S S S S
R, resistant; S, susceptible.
DeCoster et al. Susceptibility testing of M. tuberculosis 375
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 372–378
DISCUSSION
The proportion method is considered to be the
reference method for susceptibility testing of
M. tuberculosis [2,4]. The method has proven
useful in assisting clinicians to choose or conﬁrm
effective therapy for eradication of M. tuberculosis
in patients. Resistance or susceptibility is deter-
mined by comparing the number of colonies that
grow on a drug-containing plate with the number
of colonies growing on the control medium. An
isolate is considered resistant if ‡ 1% grow on the
drug-containing medium. Results are generally
available 3 weeks after inoculation of the plate
with an isolate of M. tuberculosis [2]. As the
proportion method was used as the reference
standard in the present study, the BACTEC or
ﬂow cytometric methods could not be shown to
be better than the proportion method.
Several methods have been developed that
decrease greatly the time required by the pro-
portion method to obtain susceptibility test
results [11–20]. These methods include a biolu-
minescence assay for detection of mycobacterial
ATP [11], the Gen-Probe DNA hybridisation
system [12], the luciferase reporter gene assay
[14], high-performance liquid chromatography
mycolic acid analysis [15], the Etest method [16]
and a colorimetric method [17]. However, to
date, only the BACTEC method has been recog-
nised as a valid alternative [7,8]. This method
involves measurement of 14CO2 produced by
mycobacteria growing in broth containing
14C-labelled palmitic acid with or without
anti-mycobacterial agents. Most importantly,
reproducible data are available 4–12 days after
initiation of the procedure. The BACTEC is now
accepted as a valid replacement for the propor-
tion method [4].
The present study compared susceptibility
results obtained by the proportion method with
those obtained by the ﬂow cytometric and BAC-
TEC methods for 26 clinical isolates of
M. tuberculosis. Overall, there was agreement
between the proportion and ﬂow cytometric
methods for 73 (94%) of 78 isoniazid tests, and
four of the ﬁve discrepancies were resolved with
an increase in isoniazid concentration. Complete
agreement was found for ethambutol and
rifampicin. In contrast, the proportion and BAC-
TEC methods failed to agree on 17 (22%) of the
78 isoniazid tests, and similar ﬁndings were
observed when the ﬂow cytometric and BACTEC
methods were compared. Additional discrepan-
cies were detected for rifampicin (15%) and
ethambutol (8%).
The study was based on the assumption that
the susceptibility results obtained by the propor-
tion method were correct, but selection of a sub-
population of resistant or susceptible organisms
within the cell population being tested could
have affected the results obtained. However, this
seems unreasonable on the basis of the present
data, because the overall agreement between the
proportion and ﬂow cytometric methods was
94%. Moreover, if the low concentrations (0.2
and 1 mg ⁄L) of isoniazid were eliminated from
the analysis, agreement between the methods
approached 100%. A more likely explanation for
the minor discrepancies detected with isoniazid
0.2 and 1 mg ⁄L by the proportion method is
decay of isoniazid. It is known that the bacteri-
cidal activity of isoniazid decreases rapidly in
medium after incubation for 7 days [24,25], but
little decay of isoniazid to isonicotinic acid and
other metabolites would be expected in the 24-h
period required to obtain susceptibility results by
the ﬂow cytometric method. In support of this
hypothesis, the resistant (0.2 mg ⁄L and 1 mg ⁄L)
isolates detected by the proportion method were
susceptible to even lower concentrations of isoni-
azid when retested by the ﬂow cytometric
method. Moreover, it was shown that the inocu-
lum size can affect the ﬂow cytometric results,
with increased susceptibility to isoniazid being
observed when the inoculum was decreased
from 106 to 104 CFU. This would account for
four of the ﬁve isoniazid discrepancies found
between the ﬂow cytometric and proportion
methods.
The isoniazid susceptibility results obtained by
the BACTEC method were disappointing when
compared to those obtained by the proportion
method. An explanation for the 17 discrepancies is
difﬁcult to ﬁnd, especially when the proportion
and ﬂow cytometric methods had 94% agreement.
The BACTEC results cannot, however, be attrib-
uted to faulty quality control, since only minor
variations occurred on retesting, and the reference
strains (ATCC 27294, 35822, 35838 and 35837) were
within limits. It is possible that other laboratories
would obtain similar results if the proportion
method was run concurrently with the BACTEC
method. In addition, laboratory personnel may
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require continuous training to maintain quality
with the BACTEC procedure. These steps are not
normally undertaken, but should be considered in
order to improve the quality of results.
Safety is a major concern when performing
susceptibility testing by ﬂow cytometry for
M. tuberculosis. Most laboratories will be reluctant
to use or evaluate the method because of percep-
tions that an infectious aerosol may be generated.
Although this is possible, the danger can be
prevented by killing the mycobacteria before
testing. In the present study, all data were
obtained after treating samples with paraformal-
dehyde 1% v ⁄ v, and it has been shown that
viable M. tuberculosis cells are not recovered
following treatment with paraformaldehyde for
40 min [20]. Increasing the period of exposure to
paraformaldehyde to 24 h did not alter the results
obtained by ﬂow cytometry. However, viable
M. tuberculosis cells may still be trapped in the
lips or caps of the paraformadehyde-treated
susceptibility tubes. Therefore, samples should
still be processed in a Biosafety Level 3 tubercu-
losis facility. Since few clinical and reference
mycobacterial laboratories have a ﬂow cytometer
available in or near the laboratory, susceptibility
testing by ﬂow cytometry will be limited. This
problem can be overcome by transferring the
paraformaldehyde-treated samples to a new vial
containing paraformaldehyde, whereupon the
samples are safe for processing outside the
mycobacterial laboratory. Nevertheless, expertise
with ﬂow cytometry is absolutely necessary to
ensure safety and the quality of the data. The test
is rapid and does not require multiplication of M.
tuberculosis. However, a cooperative study invol-
ving several laboratories and fresh clinical iso-
lates of M. tuberculosis is required to conﬁrm the
present results.
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